Alexandria Carlson, PhD
Postdoctoral Research Fellow
Pharmacology & Toxicology
Martin Golkowski's Lab
The Utah CTSI had the privilege of talking to Dr. Alexandria Carlson, a Spheres of Translation Across the Research Spectrum (STARS T32) program trainee. We thank her for taking the time to answer our questions about her research in cancer treatment resistance at the molecular level.
What is your area of research?
My research focuses on finding the molecular mechanisms of treatment resistance in liver cancer as well as potential therapeutics to sensitize these cancers to targeted therapies. To do this, our lab uses a variety of mass spectrometry-based proteomic techniques to determine differences in cell or tissue samples on the protein level.
What makes it relevant?
In cancer, resistance to treatment occurs in a majority of patients contributing to high mortality rates. The goal of the research in our lab is to provide a better understanding of how treatment resistance occurs in order to find novel therapeutics to sensitize cancer cells to treatment. This would result in long-lasting treatments and give patients better options.
How does it help the world?
Liver cancers are the third highest cause of cancer related death worldwide. Unfortunately, the incidence rates for liver cancers are also increasing with the rise in obesity and diabetes. By finding more effective ways of treating liver cancer, especially those with acquired resistance to treatment, we can decrease associated mortality.
How has the CTSI helped you?
As a postdoc in the STARS T32 program, the CTSI has provided countless opportunities that have helped in my career development towards becoming an independent researcher and better scientist. This includes experience in different but adjacent areas of research across the translational spectrum, opportunities for science communication and professional development, funding to continue my research, and much more.